A new study in The Lancet has shown that adding a drug called pembrolizumab to standard treatments can improve survival for people with certain types of soft tissue cancers. These cancers, known as undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, and pleomorphic liposarcoma, often affect the arms and legs. How the Clinical Trial Worked Patients were divided […]
